Navigation Links
Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
Date:9/24/2010

SAN DIEGO, Sept. 24 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the Fifth Annual JMP Securities Healthcare Conference.  The details are as follows:  Date:  Tuesday, September 28, 2010Time:  11:00am (EDT)Location: New York Palace HotelSpeaker: Graham Cooper, Chief Financial OfficerAbout Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has filed an NDA with the FDA for its lead investigational product, Contrave®.  The Company's second product, Empatic™, has completed Phase 2 clinical development.  Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches.  Further information about the Company can be found at http://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
2. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
3. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
4. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
5. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
6. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
7. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
8. Echo Therapeutics to Present at the JMP Securities Healthcare Conference
9. Precision Therapeutics President and CEO Sean McDonald Recognized as a Leading Business Executive and Recipient of 2010 Pacesetters Award
10. Echo Therapeutics Initiates Needle-Free Biosensor Program for Continuous Lactate Monitoring
11. Signum Biosciences Awarded Two Additional NIH Grants for Development of Topical Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, ... products to treat a variety of dermatological diseases, ... compound DMT210, in a Phase 2 acne rosacea ... to downregulate the proinflammatory cytokines in the skin ... acne rosacea. This clinical trial, ...
(Date:1/18/2017)... 18, 2017 The report " Automated Breast Ultrasound System ... Scanner), By End User (Hospitals, Diagnostic Imaging Centers), Industry Analysis Report, Regional Outlook ... Argentina , Germany , UK, France ... Russia , China , Japan , ... , Saudi Arabia , UAE, South Africa ...
(Date:1/18/2017)... , Jan. 18, 2017  Tarix Orphan LLC today ... granted a Rare Pediatric Disease (RPD) designation for the ... Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. ... treatment is limited to supportive care. "The ... Drug Designation previously granted by the FDA in this ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... 18, 2017 , ... Catalent Pharma Solutions, the leading global ... health products, today announced that Mr. Michael Merges, Director of Strategic Growth, Catalent ... held at the Mayflower Hotel, Washington DC, on Jan. 24 – 26, 2017. ...
(Date:1/18/2017)... ... January 18, 2017 , ... Floundering on New Year’s ... and the perfect time for a reset. The U.S. Apple Association agrees and recommends ... many of the factors that contribute to heart disease. , The U.S. Apple Association ...
(Date:1/17/2017)... ... January 17, 2017 , ... For breast cancer clinicians and ... or those who desire a more intimate review and analysis of its highlights, a ... to Bedside—is being offered by Imedex on February 4, 2017 in Chicago. Chaired by ...
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic ... National Association of Music Merchants (NAMM) winter trade show, Booth #2876, at the ... ER•4® has long been the gold standard for high-definition, in-ear earphones. This classic ...
(Date:1/17/2017)... ... January 17, 2017 , ... Peoples Health is ... Health network on Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, ... an exciting addition to our provider network, and the addition will benefit our ...
Breaking Medicine News(10 mins):